A graphene transdermal drug delivery microneedle

Abstract

The invention provides a graphene transdermal drug delivery microneedle, the base material of the microneedle is a biocompatible organic high molecular polymer used in pharmacy, and the organic high molecular polymer is uniformly dispersed with Graphene material, described organic macromolecular polymer is selected from the one in polyvinylpyrrolidone, polyvinyl alcohol, hyaluronic acid, polylactic acid-glycolic acid copolymer, carboxymethyl cellulose, and described graphene material is graphite One of graphene or graphene treated by chemical and physical methods. The graphene transdermal administration microneedle of the present invention has good mechanical properties, so that the microneedle can easily penetrate the stratum corneum; the graphene transdermal administration microneedle of the present invention has a good ability to control drug release, and can Drug release is controlled by means of infrared light; the graphene transdermal drug delivery microneedle of the present invention has comparatively excellent antibacterial properties, making the microneedle easy to preserve; the preparation method of the graphene transdermal drug delivery microneedle of the present invention is simple and low cost Low.

Description

technical field [0001] The invention belongs to the technical field of medicine and relates to a medical device, in particular to a graphene transdermal drug delivery microneedle. Background technique [0002] As a new type of transdermal drug delivery, microneedle transdermal drug delivery combines the advantages of subcutaneous injection and transdermal patch. It is not only painless and minimally invasive, but also has high drug absorption efficiency. Research is rapidly developing, especially in the treatment of epidermal lesions. However, the industrial development of polymer microneedles is still in its infancy. [0003] In terms of mechanical properties, FDA-approved excipients such as polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hyaluronic acid (HA), polylactic-co-glycolic acid (PLGA), carboxymethylcellulose (CMC) Polysaccharides such as polysaccharides can be made to form polymer microneedle structures, but the conventional heating, drying and curing metho...

AI Technical Summary

Problems solved by technology

[0003] In terms of mechanical properties, FDA-approved excipients such as polyvinylpyrrolidone (PVP), polyvinyl alcohol (PVA), hyaluronic acid (HA), polylactic-co-glycolic acid (PLGA), carboxymethylcellulose (CMC) Polysaccharides such as polysaccharides can be made to form polymer microneedle structures, but the mechanical properties that can be tolerated by conventional heating, drying and curing methods are low (each needle is mostly less than <0.1N), and PVA has been repeatedly frozen and thawed for 3-4 Second, the glass state is formed after phase transformation, which can withstand high mechanical properties, but the time is long and the operation is complicated, which is not conducive to industrial production

[0004] In terms of drug release control, the release rate of the drug can be adjusted by adjusting the ratio of the polymer, but a higher or lower polymer ratio may increase the difficulty of fabrication and affect the moldability and mechanical properties of the microneedle. question

[0005] In terms of the aseptic performance of microneedles, according to the requirements of injection preparations, special production workshops and strict operating specifications are required, and the cost is relatively high

Images